USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SOLIGENIX, INC.
Address:
29 Emmons Dr
PRINCETON, NJ 08540-5919
Phone:
N/A
URL:
N/A
EIN:
141150502
DUNS:
153880778
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,934,870.00 5

Award List:

Enteric-Coated Oral Beclomethasone Dipropionate in Patients with Acute Enteritis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$509,870.00
Agency:
HHS
Principal Investigator:
Christopher J. Schaber
Abstract:
DESCRIPTION (provided by applicant): Acute radiation enteritis is caused by radiation-induced death of the normal cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and w eeks with chronic diarrhea, vomiting and… More

Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Kevin J. Horgan – 310-206-3580
Abstract:
DESCRIPTION (provided by applicant): This proposal concerns the use of beclomethasone dipropionate (BDP) as a post-exposure drug therapy having the potential to mitigate the gastrointestinal (GI) injury associated with acute radiation syndrome (ARS) following exposure to intense ionizing radiation.… More

IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Kevin J. Horgan – 310-206-3580
Abstract:
DESCRIPTION (provided by applicant): Graft vs. Host Disease (GVHD) is an expensive life-threatening complication following allogeneic hematopoietic cell transplantation in some patients that receive this life-saving treatment for certain cancers. The proposed open-label, multi-center, two-part… More

Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Christopher J. Schaber – 609-538-8200
Abstract:
DESCRIPTION (provided by applicant): This proposal describes development of an immunomodulatory peptide that targets the host defense system for treatment of acute pneumonic melioidosis. The disease is caused by Burkholderia pseudomallei (Bps), a non-spore-forming motile saprophytic bacterium that… More

SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$225,000.00
Agency:
HHS
Principal Investigator:
Richard C. Straube – 609-538-8200
Abstract:
DESCRIPTION (provided by applicant): Oral mucositis has a significant impact on patient quality of life and outcomes during cancer therapy as well as having a significant pharmacoeconomic cost. There are no currently approved drugs to treat oral mucositisin patients with non-hematological… More